The funding will help support the Ontario Provincial ALS Program to meet the needs of the roughly 1,300 people in Ontario ...

Columnist Kristin Neva and her husband with ALS are sometimes asked about the way they went about building their accessible home.

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

Drinking straws are one of the tools in columnist Dagmar Munn's arsenal to combat dysphagia while living with ALS.

Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...

Woolsey received three new U.S. patents covering innovations related to ROCK inhibitor Bravyl (oral fasudil), its ...

Altered activity of ancient viral genes were linked to neurodegenerative diseases including ALS in a recent analysis.

Neurosense Therapeutics will meet with the FDA in early November to discuss plans for a Phase 3 trial to test PrimeC in ALS.

Signs of angels come at the most unexpected — yet vital — moments in our lives, columnist Juliet Taylor writes.

A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...